

Richard E Gilbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1893287/publications.pdf>

Version: 2024-02-01

44
papers

3,583
citations

218381

26
h-index

253896

43
g-index

44
all docs

44
docs citations

44
times ranked

5697
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
2	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
3	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
4	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
5	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
6	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet, The, 2015, 385, 2107-2117.	6.3	240
7	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
8	Inhibition of Protein Kinase C β by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy. Circulation: Heart Failure, 2009, 2, 129-137.	1.6	106
9	Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1415-H1425.	1.5	106
10	Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney International, 2014, 86, 693-700.	2.6	93
11	Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2019, 4, 27-37.	1.9	79
12	Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. Journal of Molecular and Cellular Cardiology, 2005, 39, 213-221.	0.9	70
13	DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes. Cardiovascular Therapeutics, 2013, 31, 259-267.	1.1	56
14	Acute kidney injury with sodium-glucose cotransporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1996-2000.	2.2	55
15	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	2.3	51
16	Effect of Ruboxistaurin on Urinary Transforming Growth Factor- β in Patients With Diabetic Nephropathy and Type 2 Diabetes. Diabetes Care, 2007, 30, 995-996.	4.3	50
17	Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. PLoS ONE, 2016, 11, e0144640.	1.1	47
18	Sirtuin 1 Activation Reduces Transforming Growth Factor- β -Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. American Journal of Pathology, 2017, 187, 80-90.	1.9	42

#	ARTICLE	IF	CITATIONS
19	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. <i>Cardiovascular Diabetology</i> , 2020, 19, 13.	2.7	42
20	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. <i>Journal of Hypertension</i> , 2011, 29, 1175-1184.	0.3	37
21	A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat. <i>PLoS ONE</i> , 2012, 7, e47160.	1.1	37
22	Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 2114-2125.	0.3	32
23	Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. <i>Cardiovascular Diabetology</i> , 2018, 17, 99.	2.7	32
24	SGLT2 inhibitors: \hat{I}^2 blockers for the kidney?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 814.	5.5	30
25	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. <i>Circulation</i> , 2018, 137, 88-90.	1.6	30
26	Recombinant N-Terminal Slit2 Inhibits TGF- \hat{I}^2 -Induced Fibroblast Activation and Renal Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2609-2615.	3.0	27
27	Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. <i>Diabetes Therapy</i> , 2017, 8, 451-458.	1.2	27
28	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 895-897.	0.4	22
29	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. <i>Canadian Journal of Diabetes</i> , 2021, 45, 162-166.e1.	0.4	19
30	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , 2016, 40, 247-257.	0.4	18
31	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. <i>American Journal of Medicine</i> , 2017, 130, 1465.e27-1465.e39.	0.6	17
32	Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. <i>American Journal of Pathology</i> , 2018, 188, 2763-2773.	1.9	14
33	SIRT1 activation attenuates \hat{I}^2 cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. <i>Scientific Reports</i> , 2018, 8, 13972.	1.6	13
34	Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline. <i>BMC Nephrology</i> , 2020, 21, 285.	0.8	13
35	Conditioned Medium from Early-Outgrowth Bone Marrow Cells Is Retinal Protective in Experimental Model of Diabetes. <i>PLoS ONE</i> , 2016, 11, e0147978.	1.1	13
36	Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H337-H345.	1.5	11

#	ARTICLE	IF	CITATIONS
37	Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovascular Diabetology, 2019, 18, 6.	2.7	9
38	Augmenting Endothelial Repair in Diabetes: Role of Bone Marrow-Derived Cells. Canadian Journal of Diabetes, 2013, 37, 315-318.	0.4	8
39	The perils of clinical trials. Kidney International, 2014, 85, 745-747.	2.6	5
40	The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. PLoS ONE, 2021, 16, e0252711.	1.1	5
41	Impaired SIRT1 activity leads to diminution in glomerular endowment without accelerating age-associated GFR decline. Physiological Reports, 2019, 7, e14044.	0.7	4
42	Diabetic kidney disease 2.0: the treatment paradigm shifts. Lancet Diabetes and Endocrinology, 2019, 7, 820-821.	5.5	3
43	Heart failure in SAVOR-TIMI 53: The hindsight of diabetic retinopathy. SAVOR-TIMI 53. JAMA, 2015, 314, 304-306.	0.8	1
44	Henry Krum, Pioneering Heart Failure Researcher. European Journal of Heart Failure, 2016, 18, 125-126.	2.9	0